Daiichi Sankyo Company, Limited revised earnings guidance for the full year 2022. The company expected revenue to grow due to good performance in products such as Lixiana and Injectafer and also due to ForEx impact. Therefore, the company has made an upward revision of forecast announced in April by JPY 40 billion to JPY 1.30 billion. As a result, the company has made an upward revision of core operating profit forecast by JPY 20 billion to JPY 90 billion. Operating profit forecast has been revised upward by JPY 22 billion to JPY 92 billion as booked as temporary income gains related to sale of Osaka Logistics Center in fiscal year 2020,211th quarter. Based on the upward revision of operating profit and pretax profit numbers, the company's forecast of profit attributable to owners of the company has been revised upward by JPY 14 billion or to JPY 64 billion.